GlassScriptPhysician profile
Marc W Reitman
NPI 1245395151
$13,007.25
in general payments reported to CMS, 2019-2025
34 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 87% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,231 · 2020: $1,395 · 2021: $2,254 · 2022: $3,031 · 2023: $1,414 · 2024: $1,576 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,095.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,019.43 | 2019-2025 | Trintellix |
| Abbvie INC. | $1,410.24 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,319.36 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,161.65 | 2019-2025 | Rexulti |
| Lundbeck LLC | $952.25 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $774.56 | 2020-2025 | Caplyta |
| Alkermes, INC. | $679.46 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $628.81 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $489.95 | 2019-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $371.59 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $351.25 | 2021-2023 | Qelbree |
| Corium, LLC | $330.93 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $317.24 | 2019-2025 | Aplenzin |
| Neos Therapeutics, LP | $316.88 | 2019-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $278.53 | 2019-2024 | Dyanavel Xr |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $246.30 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $185.16 | 2019-2023 | Belsomra |
| Axsome Therapeutics, INC. | $183.17 | 2024-2025 | Auvelity |
| Allergan, INC. | $158.12 | 2019-2021 | |
| Almatica Pharma LLC | $123.79 | 2021-2024 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $108.49 | 2020-2025 | Fanapt, Hetlioz |
| Neuronetics, INC. | $86.45 | 2019-2020 | |
| Shire North American Group INC | $72.80 | 2019 | |
| Idorsia Pharmaceuticals US INC | $66.68 | 2022-2023 | Quviviq |
| Alfasigma USA, INC. | $62.94 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $49.20 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $47.68 | 2019 | |
| Noven Therapeutics, LLC | $43.95 | 2020 | |
| Arbor Pharmaceuticals, INC. | $40.01 | 2019 | |
| Eisai INC. | $37.90 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.74 | 2025 | Cobenfy |
| Novo Nordisk INC | $21.85 | 2022 | |
| Avanir Pharmaceuticals, INC. | $21.79 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Reitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.